Abstract
Ischemic bowel necrosis in the rat is produced by injecting platelet-activating factor (PAF) intravenously. Since intestinal hypoperfusion is observed after PAF injection, we hypothesize that mesenteric vasoconstriction is the mechanism of bowel injury. We thus studied the effects of vasodilators in this model. We found that: (1) Phenoxybenzamine, prazosin, ICI 198615 (leukotriene antagonist) and PGE1 counteracted the PAF-induced mesenteric flow reduction and ameliorated the bowel injury. However, phenoxybenzamine and prazosin were relatively ineffective in correcting PAF-induced hypotension, showing that bowel injury can be prevented independently of the hypotensive state. (2) Nitroglycerin failed to prevent bowel injury, although it improved the mesenteric blood flow. Thus, in opposition to our initial hypothesis, correction of the mesenteric flow reduction induced by PAF does not always prevent intestinal necrosis. (3) Only phenoxybenzamine, prazosin, ICI 198615, and PGE1 ameliorated PAF-induced hemoconcentration and bowel injury. This suggests a correlation between vascular injury (expressed by “leaky” vessels and the consequent hemoconcentration) and bowel necrosis. (4) Although both nitroglycerin and hydralazine relax smooth muscle, hydralazine seemed to aggravate bowel necrosis. The mechanism remains unclear.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Benveniste J: PAF-acether, an ether phospholipid with biological activity.In Biological Membranes: Aberrations in Membrane Structure and Function. ML Karnovsky, LC Bolis, (eds). New York, Alan R. Liss, 1988, pp. 73–85.
Hanahan DJ: Platelet activating factor: A biologically active phosphoglyceride. Annu Rev Biochem 55:483–509, 1986
Chignard M, LeCouedic JP, Tence M, Vargaftig BB, Benveniste J: The role of Platelet-activating factor in platelet aggregation. Nature 279:799–800, 1979
O'Flaherty J, Wykle RL, Miller CH, Lewis JC, Waite M, Bass DA, McCall CE, DeChatelet LR: 1-o-alkyl-sn-glyceryl-3-phosphorylcholines. A novel class of neutrophil stimulants. Am J Pathol 103:70–79, 1981
Dewald B, Baggiolini M: Platelet-activating factor as a stimulus of exocytosis in human neutrophils. Biochim Biophys Acta 888:42–48, 1986
McManus LM, Hanahan DJ, Demopoulos CA, Pinckard RN: Pathobiology of the intravenous infusion of acetyl glycery ether phosphorylcholine (AGEPC), a synthetic platelet-activating factor (PAF), in the rabbit. J Immunol 124:2919–2924, 1980
Halonen M, Palmer JD, Lohman C, McManus LM, Pinckard RN: Respiratory and circulatory alterations induced by acetyl glyceryl ether phosphorylcholine. A mediator of IgE anaphylaxis in the rabbit. Am Rev Respir Dis 122:915–924, 1980
Bessin P, Bonnet J, Apffel D, Soulard C, Desgroux L, Pelas I, Benveniste J: Acute circulatory collapse caused by platelet-activating factor (PAF-acether) in dogs. Eur J Pharmacol 86:403–413, 1983
Gonzalez-Crussi F, Hsueh W: Experimental model of ischemic bowel necrosis. The role of platelet activating factor and endotoxin. Am J Pathol 112:127–135, 1983
Hsueh W, Gonzalez-Crussi F, Arroyave JL: Platelet activating factor induced ischemic bowel necrosis. An investigation of secondary mediators in its pathogenesis. Am J Pathol 122:231–239, 1986
Hsueh W, Gonzalez-Crussi F, Ischemic bowel necrosis induced by platelet-activating factor: An experimental model. Methods Achiev Exp Pathol 13:208–239, 1988
Kasuya Y, Masuda Y, Shigenobu K: Possible role of endothelium of the vasodilator response of rat thoracic aorta to platelet activating factor. J Pharmacobiodyn 7:138–142, 1984
Hsueh W, Gonzalez-Crussi F, Arroyave JL: Release of leukotriene C4 by isolated perfused rat small intestine in response to platelet activating factor. J Clin Invest 78:108–114, 1986
Hsueh W, Gonzalez-Crussi F, Arroyave JL: Sequential release of leukotrienes and norepinephrine in rat bowel after platelet-activating factor. Gastroenterology 94:1412–1418, 1988
Snyder DW, Giles RE, Keith RA, Yee YK, Krell RD:In vitro pharmacology of ICI 198,615: A novel, potent and selective peptide leukotriene antagonist. J Pharmacol Exp Ther 243:548–557, 1987
Cueva JP, Hsueh W: Role of oxygen derived free radicals in platelet activating factor induced bowel necrosis. Gut 29:1207–1212, 1988
Needleman P, Marshall GR, Johnson EM Jr: Determinants and modification of adrenergic and vascular resistance in the kidney. Am J Physiol 227:665–669, 1974
Robert A: Protection against mucosal damage: Mechanism of action of eicosanoids.In Advances in Eicosanoid Research. K Hillier (ed). Eicosanoids and the Gastrointestinal Tract. MTP Press Limited, Lancaster, England. 1988, pp 103–110.
Braquet P, Etienne A, Mencia-Huerta J-M, Clostre F: Effects of the specific platelet-activating factor antagonists, BN 52021 and BN 52063, on various experimental gastrointestinal ulcerations. Eur J Pharmacol 150:269–276, 1988
Siren A-L, Feuerstein G: Effects of PAF and BN 52021 on cardiac function and regional blood flow in conscious rats. Am J Physiol 257:H23-H32, 1989
Kubes P, Suzuki M, Granger DN: Platelet-activating factor-induced microvascular dysfunction: Role of adherent leukocytes. Am J Physiol 258:G158-G163, 1990
Rosam A-C, Wallace JL, Whittle BJR: Potent ulcerogenic actions of platelet activating factor on the stomach. Nature 319:54–56, 1986
Author information
Authors and Affiliations
Additional information
This work was supported by NIH grant DK 34574.
Rights and permissions
About this article
Cite this article
Zhang, C., Hsueh, W. PAF-induced bowel necrosis. Digest Dis Sci 36, 634–640 (1991). https://doi.org/10.1007/BF01297031
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01297031